Teriparatide (PTH 1-34)
FDA-approved osteoporosis drug — and the widest gap between vial size and clinical dose here.
For research purposes only. These products are not intended to diagnose, treat, cure, or prevent any disease. By purchasing, you confirm these products will be used for legitimate research purposes.
About Teriparatide (PTH 1-34)
Teriparatide is the first 34 amino acids of parathyroid hormone, approved as Forteo for osteoporosis in patients at high risk of fracture. It is the clearest example in this catalog of intermittent versus continuous dosing mattering: given once daily it stimulates bone formation and increases bone mineral density, whereas chronically elevated PTH does the reverse and drives bone resorption. The label dose is 20 micrograms once daily by subcutaneous injection. That number deserves attention against what research vendors sell. A 10mg research vial contains roughly 500 daily clinical doses, so a reconstitution or measurement error here is not a matter of a slightly strong dose. The osteosarcoma history is also frequently misreported: rats given near-lifetime high doses developed osteosarcoma, which produced an original boxed warning and a two-year lifetime limit, but real-world evidence showed no increased osteosarcoma risk in treated adults, and in 2020 the FDA removed the boxed warning and revised the duration limit. The current label states that no increased risk was observed in adult humans.
Key Benefits
- FDA-approved with large fracture-outcome trial evidence
- Anabolic for bone — builds new bone rather than only slowing loss
- Increases bone mineral density at the spine and hip
- Boxed warning removed in 2020 following real-world safety data
Set a goal (top of the page) to see how Teriparatide (PTH 1-34) scores against it, and what the better-evidenced alternatives are.
Category Ratings
How to Take
Common Side Effects
- Orthostatic hypotension, particularly after the first few doses
- Nausea
- Headache
- Leg cramps
- Hypercalcaemia
- Elevated uric acid
- Injection site reactions
- Osteosarcoma was seen in rats at near-lifetime high doses; no increased risk has been observed in treated adults
Legal & Regulatory Status
Prescription only. FDA-approved as Forteo (also Bonsity) for osteoporosis in patients at high risk of fracture. Research-grade vials are explicitly not the approved pharmaceutical formulation and are not sold for human use.
Safety and regulatory details for FDA-approved compounds are drawn from the official product label via openFDA; clinical development status reflects ClinicalTrials.gov. This information is provided for research reference, is not endorsed by the FDA, and may not be complete or current.
Research & Sources
- FORTEO (teriparatide) label, 2020 — post-boxed-warning-removal version (FDA)
- Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning (PMC9465003)
- Teriparatide and osteosarcoma risk — label update analysis (PMID 36111201)
Sources are selected for reliability (peer-reviewed literature, openFDA, ClinicalTrials.gov) but this is a research summary, not medical advice, and may not be exhaustive.
Prices at quality-checked sources · as of August 2026 (8 days ago)
- 10mg $124.99
Observed on each vendor’s public listing — see how these sources are vetted. Peptide Concierge doesn’t sell peptides and isn’t affiliated with any vendor; confirm current pricing at the source.
Builds a working set shared across the stack builder, calculator, scheduler and compare.